Objective-We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. Methods and Results-We studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control subjects. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100 kinetics were determined in the fed state using stable isotope methods and compartmental modeling. Compared with controls, familial LPL deficiency had markedly elevated plasma triglycerides and lower VLDL-apoB-100 fractional catabolic rate (FCR), IDL-apoB-100 FCR, VLDL-to-IDL conversion, and VLDL-apoB-100 production rate (PϽ0.01). Compared with controls, Gly188Glu had higher plasma triglyceride and VLDL-and IDL-apoB-100 concentrations and lower VLDL-and IDL-apoB-100 FCR (PϽ0.05). Plasma triglycerides were not different, but IDL-apoB-100 concentration and production rate and VLDL-to-IDL conversion were lower in Trp64Stop compared with controls (PϽ0.05). No differences between controls and Ile194Thr were observed. Conclusion-Our results confirm that hypertriglyceridemia is a key feature of familial LPL deficiency. This is due to impaired VLDL-and IDL-apoB-100 catabolism and VLDL-to-IDL conversion. Single-allele mutations of the LPL gene result in modest to elevated plasma triglycerides. The changes in plasma triglycerides and apoB-100 kinetics are attributable to the effects of the LPL genotype. (Arterioscler Thromb Vasc Biol. 2012;32:459-466.)
primarily by adipocytes and muscle cells into the bloodstream, where it is bound to endothelial cells by glycosaminoglycans, such as heparan sulfate. 1 LPL plays a central role in triglyceride metabolism. In the presence of its cofactor, apolipoprotein C-II (apoC-II), 2 LPL hydrolyzes the triglyceride-core of circulating triglyceride-rich lipoprotein (TRL) particles to generate free fatty acids and glycerol for subsequent use by muscle, liver, heart, and adipose tissues for energy use or storage, or as substrates for lipoprotein formation. 3 LPL also mediates cellular uptake and removal of TRL and their remnants from the circulation by binding these lipoproteins to cell surface proteins, including the low-density lipoprotein (LDL) receptor, very low-density lipoprotein (VLDL) receptor, LDL receptor-related protein and apoE receptor 2. 4 -9 The human LPL gene spans Ϸ30 kb on the short arm of chromosome 8 and is composed of 10 exons coding for a 448-amino-acid protein. 10 Familial LPL deficiency is a rare autosomal recessive trait (1 in a million) and is the most frequent defect underlying type I hyperlipoproteinemia (familial chylomicronemia syndrome). 11, 12 The presence of 2 defective LPL alleles in homozygous or compound heterozygous forms results in negligible or low levels of LPL activity. Consequently, these subjects have severe hypertriglyceridemia and low high-density lipoprotein (HDL) cholesterol concentrations but an unexpectedly low risk of premature coronary heart disease. By contrast, subjects heterozygous for the LPL gene (1 in 500) have modest to elevated concentrations of plasma triglyceride and low HDL cholesterol relative to the general population 11, 12 and increased coronary heart disease risk. 11, 13 The majority of molecular defects in the LPL gene are clustered in exons 5 and 6, with other mutations found in exons 3, 4, and 8. 14 Of these, 2 missense mutations in exon 5 (Gly188Glu and Ile194Thr) and 1 nonsense mutation in exon 3 (Trp64Stop) have been associated with hypertriglyceridemia. 15 Of note, subjects heterozygous for the Gly188Glu mutation have 78% higher plasma triglyceride concentrations than the general population. 11 Much less is known about the lipid profile of subjects heterozygous for the Ile194Thr and Trp64Stop mutations. No studies, to date, have examined the effects on these LPL mutations on human lipoprotein metabolism.
The aim of this study was 2-fold. The first aim was to determine that subjects who were homozygous or compound heterozygous for the Gly188Glu, Ile194Thr, Ile207Pro, or Trp64Stop mutations have altered apoB-100 metabolism. Two compound heterozygous subjects and 1 homozygous subject were identified and compared with 10 age-and sex-matched healthy controls. The second aim was to determine the effect of single-allele mutations of Gly188Glu, Ile194Thr, and Trp64Stop on apoB-100 metabolism. Fourteen subjects identified to have a single allele of 1 of these LPL mutations were compared with the same 10 age-and sex-matched healthy controls.
Methods

Subjects
At the time of this study, the Cincinnati Lipid Clinic was treating 4 subjects with familial LPL deficiency as identified by fasting triglycerides Ն11.0 mmol/L (1000 mg/dL), and of these, 3 subjects consented to participate in this study. 16 DNA analysis was performed and the first subject was identified to be a compound heterozygous, with a missense mutation corresponding to a substitution of threonine for isoleucine (ATT3 ACT) at amino acid 194 (Ile194Thr) on 1 allele and a missense mutation causing a substitution of glutamic acid for glycine (GGG3 GAG) at amino acid 188 (Gly188Glu) on the other allele. The second subject was identified as a compound heterozygous with Gly188Glu mutation on 1 allele and a missense mutation corresponding to a substitution of proline for leucine at amino acid 207 on the other allele (CCG3 CTG) (Ile207Pro). The third subject was identified as a homozygous for the Gly188Glu mutation. The fourth subject was identified to be a compound heterozygous with the Trp64Stop and Ile194Thr mutations but declined to participate in the kinetic study.
A total of 152 family members, excluding the probands, were recruited. 16 Thirty-eight subjects were found to carry a mutation of the LPL gene on 1 allele: 8 subjects had the Trp64Stop mutation, 14 had the Ile194Thr mutation, and 16 had the Gly188Glu mutation. Of these subjects, 5 with the Trp64Stop mutation, 5 with the Ile194Thr mutation, and 4 with the Gly188Glu mutation consented to participate in the kinetic study.
Data for 10 age-and sex-match healthy controls were available from a previous study 17 ; the methods applied for determination of kinetic parameters were similar to this study. Exclusion criteria were chronic illness, including endocrine, hepatic, renal, thyroid, or cardiac dysfunction; smoking; consumption of Ն2 alcoholic drinks per day; and current use of medications known to affect lipid metabolism (lipid lowering drugs, fish-oil capsules, beta blockers, or diuretics).
The protocol was approved by the institutional review board of the University of Cincinnati, the Tufts University School of Medicine, and the Tufts Medical Center Human Investigation Review Committee. All subjects provided written consent. The study was completed before the development of the ClinicalTrials.gov registry.
DNA Analysis
LPL gene defects for each compound heterozygous and homozygous were determined or confirmed by polymerase chain reaction-amplified exons of their genomic DNA. 16 A combination of sequencing, restriction endonuclease digestion, and oligonucleotide hybridization was used to ascertain the presence of the defect. Direct sequencing was performed according to the procedures described by Ameis et al. 18 To determine whether the heterozygous subjects had the mutation in 1 allele, dot blot hybridization was performed with a modified procedure based on the method of Henderson et al using 50 ng of amplified exon 3 or exon 5 DNA. 19 Normal and mutant oligomers were, respectively: 5Ј-TTTT GGCACCCAACTCTCATA-3Ј and 5Ј-TATGAGAGTTAGGTGC CAAAA-3Ј for the codon 64 substitution and 5Ј-TGGATTCCAATG CTTCGAC-3Ј and 5Ј-GTCGAAGCACTGGAATCCA-3Ј for the codon 194 substitution. Each family member was screened for the mutation using this technique. AvaII digestion of exon 5, amplified by polymerase chain reaction and visualized using ethidium bromide, permitted identification of subjects heterozygous for the codon 188 substitution. The reaction conditions for polymerase chain reaction were denaturation at 94°C for 1 minute, annealing at 60°C for exon 3 and 64°C for exon 5 for 30 seconds, and extension at 72°C for 2 minutes. This reaction was performed for 30 cycles on a DNA thermal cycler (PerkinElmer-Cetus). 20
Dietary Intervention
Heterozygous and control subjects consumed a standardized, weight maintaining, Western-type diet providing 49% energy from carbohydrate, 15% energy from protein, 36% from fat (15% saturated fatty acids, 15% monounsaturated fatty acids, and 6% polyunsaturated fatty acids), and 180 mg cholesterol/1000 kcal for 3 weeks before the infusion study. Compound heterozygous and homozygous subjects consumed a standardized weight maintaining diet providing 59% energy from carbohydrate, 15% energy from protein, 26% energy from fat (11% saturated fatty acids, 11% monounsaturated fatty acids, and 4% polyunsaturated fatty acids), and 180 mg cholesterol/ 1000 kcal for 3 weeks before the infusion study. All meals were prepared by the Metabolic Research Unit Kitchen of Cincinnati Lipid Clinic (subjects with LPL mutations) or the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University (control subjects). Meals were collected by the subjects 4 times per week. Subjects were allowed to eat and drink only items provided, except for water and noncaloric beverages. Subjects were advised to maintain a constant level of physical activity.
Measurement of Lipoprotein Kinetics
At the end of the controlled dietary phase, a primed, constant infusion of deuterated leucine (5,5,5-2 H 3 -L-leucine, Cambridge Isotope Laboratories, Andover, MA) was administered intravenously in the fed state to determine the kinetics of apoB-100-containing lipoproteins, as previously described. 17 In brief, following a 12-hour overnight fast, subjects were provided with the experimental meal on an hourly basis for 20 hours. The amount of food provided at each hour was 5% of the daily energy intake. The composition of the portioned meal approximated that of the diet that was provided before the infusion period. Five hours after the first meal, a bolus dose of deuterated leucine (10 mol/kg) was administered, followed by a 15-hour infusion of deuterated leucine (10 mol/kg per hour). Blood samples were collected before the isotope infusion (timeϭ0 minute) and at 25, 35, and 45 minutes and 1, 1.5, 2, 4, 6, 9, 12, and 15 hours during the infusion. All isotope solutions were prepared at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University.
The protocol for plasma lipid and lipoprotein characterization, quantification, and isolation of the apolipoproteins; isotopic enrichment determinations; and kinetic analyses were performed as previously described 17 (see Supplemental Data, available online at http://atvb.ahajournals.org, for full description of methods). Fasting lipid and apolipoprotein values were averages of 3 measurements taken at the end of the controlled feeding period. Nonfasting lipid and apolipoprotein values were averages of 5 measurements corresponding to time points of 1, 4, 8, 12, and 15 hours during the infusion study.
Kinetic Analysis
A multicompartmental model ( Figure) was used to describe VLDL-, intermediate-density lipoprotein (IDL)-, and LDL-apoB-100 kinetics. The SAAM II program (University of Washington, Seattle, WA) was used for modeling the data. The details and assumptions of the model were described previously. 17 The fractional catabolic rates (FCRs) of VLDL-, IDL-and LDL-apoB-100 were derived from the model parameters giving the best fit. The corresponding production rates (PRs) were calculated as the product of FCR and pool size, which equals the plasma concentration multiplied by plasma volume (4.5% of body weight in kilograms).
Statistical Analysis
Data are presented as meanϮSEM unless stated otherwise. Skewed variables were logarithmically transformed where appropriate. Data among groups were compared using general linear models (SAS Proc GLM, SAS Institute). All pairwise comparisons and their corresponding probability values for the test of no difference are reported, with statistical significance set at the 5% level. The number of subjects included in the study was small. As such, the use of Bonferroni adjustments of probability values was not applied. Table 1 shows the clinical and biochemical characteristics of our study subjects. Subjects who were compound heterozygous and homozygous for the LPL gene and healthy controls were well matched for age, sex, and body weight. Of note, these affected subjects carried at least 1 Gly188Glu mutation. They had, on average, fasting and postprandial plasma triglyceride concentrations that were significantly higher than healthy controls. These subjects also had fasting HDL cholesterol concentrations that were, on average, significantly lower than healthy controls. Table 2 shows the concentrations and kinetics of VLDL-, IDL-, and LDL-apoB-100. Compared with healthy controls, the compound heterozygous and homozygous subjects had, on average, LDL-apoB-100 concentrations that were signifi- The apoB-100 model consisted of 6 compartments. Compartment 1 represents the precursor compartment, which is the plasma leucine pool. Compartment 2 is an intracellular delay compartment that accounts for the synthesis and secretion of apoB-100 into the VLDL pool (compartment 3). Compartments 3 and 4 account for the kinetics of apoB-100 in the VLDL fraction. Compartment 5 accounts for the kinetics of IDL-apoB-100. The kinetics of LDL-apoB-100 are described by a plasma compartment (compartment 6). cantly lower. VLDL-and IDL-apoB-100 concentrations were, on average, higher, but these failed to reach statistical significance. VLDL-and IDL-apoB-100 FCRs were, on average, significantly lower than that observed in healthy controls. LDL-apoB-100 FCR was not different between the compound heterozygous and homozygous subjects compared with healthy controls. On average, VLDL-to IDL-apoB-100 conversion and VLDL-, IDL-and LDL-apoB-100 PR were significantly lower in these subjects compared with healthy controls.
Results
Compound Heterozygous/Homozygous Subjects (Familial LPL Deficiency)
Heterozygous Subjects
Subjects heterozygous for the LPL gene and healthy controls were well matched for age and sex (Table 1) . Subjects with the Trp64Stop mutation had, on average, significantly higher body weights compared with subjects with the Ile194Thr or Gly188Glu mutations. Hence, adjustment for body weight differences between groups was performed in all subsequent analyses. Compared with healthy controls, subjects with the Gly188Glu mutation had significantly lower fasting and postprandial HDL cholesterol concentrations. Postprandial, but not fasting, HDL cholesterol concentrations were significantly lower in these subjects compared with those with the Ile194Thr or Trp64Stop mutations. Compared with healthy controls, subjects with the Gly188Glu mutation had significantly higher fasting and postprandial plasma triglyceride concentrations. Fasting and postprandial plasma triglyceride concentrations were also higher in subjects with the Gly188Glu mutation compared with subjects with the Ile194Thr or Trp64Stop mutations. Postprandial VLDL cholesterol concentration was higher in subjects with the Gly188Glu mutation compared with healthy controls and subjects with the Ile194Thr or Trp64Stop mutations. There were no significant differences for any of the above parameters among healthy controls, subjects with the Ile194Thr mutation, and subjects with the Trp64Stop mutation. Fasting and postprandial total and LDL cholesterol were not different between the groups (Table 1) . Individual data are provided in the Supplemental Tables.  Compared with healthy controls, subjects with the Gly188Glu mutation had significantly higher VLDL-and IDL-100 concentrations ( Table 2) . VLDL-and IDL-apoB-100 concentrations were also higher in subjects with the Gly188Glu mutation compared with subjects with the Ile194Thr or Trp64Stop mutations. Compared with healthy controls, subjects with the Trp64Stop mutation had significantly lower in IDL-apoB-100 concentrations. IDL-apoB-100 concentrations were also lower in subjects with the Trp64Stop mutation compared with subject with the Ile1964Thr or Gly188Glu mutations. No significant differences were observed among healthy controls and subjects with the Ile194Thr mutation for VLDL and IDL-apoB-100 Table 2 concentrations. LDL-apoB-100 concentrations were not significantly different among the groups (Table 2) . Compared with healthy controls, subjects with the Gly188Glu mutation had significantly lower VLDL-and IDL-apoB-100 FCR ( Table 2) . VLDL-apoB-100 FCR, but not IDL-apoB-100, was also significantly lower in these subjects compared with subjects who had the Ile194Thr or Trp64Stop mutations. There were no significant differences among healthy controls and subjects with the Ile194Thr or Trp64Stop mutations for VLDL-and IDL-apoB-100 FCR. LDL-apoB-100 FCR was not different among the groups.
. Kinetic Characteristics of VLDL-, IDL-, and LDL-apoB-100 of Study Subjects
Compared with healthy controls, subjects with the Gly188Glu mutation had significantly lower VLDL-apoB-100 PR ( Table 2 ). VLDL-apoB-100 PR was not different between the 3 groups of subjects heterozygous for an LPL mutation. Compared with healthy controls, subjects with the Trp64Stop mutation had significantly lower IDL-apoB-100 PR. IDL-apoB-100 PR was also significantly lower in these subjects compared with subjects with the Ile194Thr or Gly188Glu mutations. IDL-apoB-100 PR was not different among healthy controls and subjects with the Ile194Thr or Gly188Glu mutations. There were no significant differences among the groups in LDL-apoB-100 PR.
Compared with healthy controls, the conversion of VLDLto IDL-apoB-100 was lower in subjects with the Trp64Stop mutation ( Table 2 ). The conversion of VLDL-to LDL-apoB-100 was higher in these subjects, but the difference failed to reach statistical significance (Pϭ0.07). The conversion of VLDL-to IDL-apoB-100 was also significantly lower in subjects with the Trp64Stop mutation compared with subjects with the Ile194Thr or Gly188Glu mutations.
Discussion
We provide new information on the impact of different LPL gene mutations on apoB-100 metabolism in the fed state (Table 3 ). We confirmed that severe hypertriglyceridemia is a feature of familial LPL deficiency, due to impaired VLDLand IDL-apoB-100 catabolism and VLDL-to IDL-apoB-100 conversion. We showed that the presence of heterozygous Gly188Glu mutation was associated with fasting and postprandial hypertriglyceridemia. These subjects also had higher VLDL-and IDL-apoB-100 concentrations due to lower VLDL-and IDL-apoB-100 FCR. We also showed that the presence of heterozygous Trp64Stop mutation was not associated with hypertriglyceridemia or altered VLDL-apoB-100 concentration and kinetics. This mutation, however, altered IDL-apoB-100 concentration and PR, as well as the conversions of VLDL-to IDL-apoB-100. The heterozygous Ile194Thr mutation was not associated with hypertriglyceridemia or altered apoB-100 metabolism.
Radiokinetic studies that examined the impact of LPL deficiency on apoB-100 metabolism focused on subjects who phenotypically had type I hyperlipoproteinemia. Nicoll and Lewis reported that apoB-100 metabolism was unaltered in 1 LPL deficient subject. 21 By contrast, Stalenhoef et al reported that apoB-100 and apoB-48 catabolism and the conversion rates of large VLDL to LDL were impaired in 2 LPL deficient subjects. 22 Similarly, Demant et al reported, in 3 subjects, that LPL deficiency primarily affects VLDL 1 metabolism by delaying its direct catabolism and conversion to VLDL 2 particles, resulting in an expanded VLDL 1 -apoB-100 pool. 23 VLDL-apoB-100 secretion and lipolysis further down the delipidation cascade were within the normal range. 23 Our study is consistent with prior reports that VLDL-apoB-100 FCR was impaired in familial LPL deficiency. However, in contrast to these reports, we found that these subjects also had diminished VLDL-apoB-100 PR. This may be attributed to lower free fatty acid flux to the liver, a key determinant of hepatic apoB-100 synthesis and secretion, as a consequence of impaired hydrolysis of TRL particles (VLDL and chylomicrons), by peripheral tissues in the absence of functional LPL. 24, 25 In addition, the lower VLDL-apoB-100 PR, together with the slower VLDL-apoB-100 FCR, meant that no expansion of the VLDL-apoB-100 pool was observed. The lower IDL-and LDL-apoB-100 PR and, consequently, the lower LDL-apoB-100 concentrations were likely due to diminished conversion of VLDL to IDL particles in the absence of functional LPL.
To date, only 1 study has examined the effect of partial LPL deficiency on apoB-100 metabolism. Pérez-Méndez et al, using stable isotope methodologies, reported that a heterozygous carrier of a Ser244Thr missense mutation had a 4-fold slower VLDL-apoB-100 FCR compared with a heterozygous carrier of a transition in the 3Ј splice site of intron 2 (AG-AA) in the LPL gene, with comparable postheparin plasma LPL activity. 26 No studies have examined the impact of single-allele Gly188Glu, Ile194Thr, or Trp64Stop mutations on apoB-100 kinetics.
Consistent with earlier studies, subjects heterozygous for the Gly188Glu had elevated plasma triglyceride concentra- tions. 11, [27] [28] [29] We showed that these subjects also had higher VLDL-and IDL-apoB-100 concentrations due to delayed VLDL-and IDL-apoB-100 catabolism. Peterson et al reported that Gly188Glu mutant LPL proteins have impaired catalytic and esterase activities, do not form stable dimers, and have diminished ability to bind to heparin sulfate proteoglycans. 30 In addition, the predicted 3D structure of LPL indicate that the 188 residue is located on the hydrophobic surface loops and that the Gly188Glu mutation would result in altered LPL substrate recognition and binding. 31 These structural and functional consequences specific to the Gly188Glu mutation are consistent with previous studies reporting a 50% reduction in LPL activity in subjects heterozygous for the Gly188Glu mutation 11 and, therefore, the delayed catabolism and accumulation of VLDL and IDL particles in plasma.
That VLDL was converted to IDL and LDL within the normal range in subjects heterozygous for the Gly188Glu mutation is likely explained by the presence of some functional plasma LPL proteins. We propose that LPL dimerization on the endothelial surface could include several permutations of mutant and normal proteins. Based on stochastic processes, 25% of the dimers in subjects heterozygous for the Gly188Glu mutation could be functional. It is also plausible that hepatic lipase contributes to the lipolysis of VLDL particles. Studies have reported normal hepatic lipase activity despite absent or impaired LPL activity in subjects with LPL gene mutations. 32, 33 Consistent with this notion, conversion of VLDL to IDL particles, albeit delayed, was observed in the compound heterozygous and homozygous subjects.
We previously described the Trp64Stop mutation in a compound heterozygous lacking postheparin plasma LPL activity presented with severe hypertriglyceridemia. 15 Subjects heterozygous for the Trp64Stop mutation, on the other hand, have normal LPL activities and masses and normal plasma triglyceride concentrations. 15, 16 Consistent with this, our subjects heterozygous for Trp64Stop mutation also did not have elevated plasma triglyceride concentrations. However, these subjects had IDL-apoB-100 concentrations that were markedly lower because of impaired VLDL to IDL conversion. Small fragments of the LPL protein, a result of mutations that cause truncation of the LPL proteins, are rapidly degraded before entering the endoplasmic reticulum and hence cannot form functional dimers. 34, 35 Subjects heterozygous for the Trp64Stop mutation, however, had normal LDL-apoB-100 concentrations. This may be, in part, due to preferential conversion of VLDL to LDL particles. Packard et al reported that small, dense VLDLs are preferentially converted to LDL particles. 36 It is possible that the presence of the Trp64Stop mutation resulted in altered VLDL composition and size, but this requires further investigation.
Previous studies of subjects heterozygous for the Ile194Thr mutation reported levels of LPL activity that ranged from normal to impaired and, consequently, a wide range of plasma triglyceride concentrations. 37 Our subjects heterozygous for the Ile194Thr mutation did not have elevated plasma triglyceride concentrations and were, on average, metabolically normal. We propose that the normal LPL protein, in these carriers, mitigated the expression of the Ile194Thr mutant such that, on average, LPL functionality was preserved. Consistent with this, we observed that the Gly188Glu/ Ile194Thr compound heterozygous subject had a VLDL-apoB-100 FCR that was 2-fold higher and a VLDL to IDL conversion that was 3-fold higher than that of the Gly188Glu homozygous subjects.
This study has limitations. We were unable to obtain LPL and hepatic lipase masses and activities, which may have clarified the mechanisms for altered lipoprotein kinetics in these subjects. However, Pérez-Méndez et al examined 2 individuals with a Ser244Thr missense mutation and a transition in 3Ј splice site of intron 2 (AG-AA) in the LPL gene. 26 Both subjects had approximately 50% LPL activity in postheparin plasma compared with controls. Only the Ser244Thr carrier was hypertriglyceridemic. VLDL apoB FCR was 4-fold slower in this subject compared with the AG-AA subject. The authors proposed that these observations were dependent on the site of the mutation rather than enzyme activity. Therefore, understanding the impact of LPL gene mutations on apoB-100 metabolism per se is clinically relevant. The kinetics of VLDL subspecies and VLDL triglycerides were not examined, but we anticipate that their catabolism will also be reduced in subjects with the Gly188Glu mutation. The effect of LPL is closely related to its cofactor apoC-II and its inhibitor, apoC-III. 11, 38, 39 ApoB-100-containing particles may exhibit kinetic and structural heterogeneity based on the content of these regulatory apolipoproteins, as well as apoE. 40 Measurement of the concentrations and kinetics of key regulatory apolipoproteins in plasma may further corroborate our findings. It is also important to acknowledge the possibility the LDL particles isolated, or a fraction thereof, contain Lp(a). 41 In addition, some IDL and LDL particles may represent the spillover of particles from the small VLDL density fraction. Future studies to further characterize these particles within their respective density ranges are warranted. Linkage disequilibrium with other causative mutations nearby cannot be excluded. To date, none has been identified for the Gly188Glu mutation. Less is known of the Trp64Stop and Ile194Thr mutations. The kinetics of apoB-48 were not examined in our subjects. Previous studies in LPL deficient subjects suggest that the catabolism of apoB-48-containing lipoproteins is impaired. 22 Future studies to examine the effects of LPL on HDL metabolism are also warranted. 42 This study does provide key insights into the important relationship between heterozygous LPL mutations and coronary heart disease risk. Of interest, the size of VLDL particles (triglyceride content) is a determinant of the metabolism of lipoprotein particles in the circulation. This entails concerted actions of lipolytic enzymes, regulatory apolipoproteins, and lipid transfer proteins. It is probable that heterozygous LPL deficient subjects, reviewed by Wittrup et al 11 and Brunzell, 12 particularly those with hypertriglyceridemia, have altered lipoprotein profile, favoring a higher proportion of large, triglyceride-enriched VLDL particles. These particles have delayed catabolism, as observed in subjects heterozygous for the Gly188Glu mutation. An atherogenic consequence of delayed catabolism of apoB-100-containing lipoprotein particles, particularly triglyceride-rich VLDL, is the production of small dense LDL and low concentrations of HDL particles due to cholesteryl ester transfer protein-mediated exchange of triglyceride and cholesterol between TRL and HDL particles. [43] [44] [45] In addition, the increased residence time of TRL particles in vivo may result in a greater prospect of these particles undergoing oxidative modification, taken up by macrophages to form foam cells and, ultimately, atheroma. 46 In light of the growing evidence that elevated plasma triglyceride concentrations are independent risk factors for premature coronary heart disease, understanding the genetic determinants of TRL metabolism is clinically important. Our study confirmed that hypertriglyceridemia is a key feature of familial LPL deficiency and that in these subjects, VLDLand IDL-apoB-100 catabolism and VLDL-to IDL-apoB-100 conversion are consistently impaired in the fed state. By contrast, single-allele mutations of the LPL gene resulted in modest to elevated plasma triglyceride concentrations. The effect on plasma triglyceride concentrations and apoB-100 kinetics, in these subjects, was dependent on the impact of the LPL genotype. Future studies with appropriate interventions, including gene therapy, particularly in subjects with hypertriglyceridemia, are awaited with interest.
